MedTech growth concerns likely to overshadow Q3 results, Leerink says
XLV•Leerink Partners remains cautious about the MedTech sector ahead of Q3 earnings, saying growth concerns for 2027 and beyond could overshadow even positive results.
1. Sector outlook
Leerink cited a "somewhat murky" near-term backdrop, including competition in cardiac devices and diabetes care, uncertain procedure volumes amid higher costs, weakening consumer sentiment and hospital budget pressure from rising interest rates. It said company-specific catalysts could help Medtronic and Tandem Diabetes Care outperform sector headwinds, while slowing adoption and rising competition could lead to downward revisions to 2027 expectations for PROCEPT BioRobotics and Insulet.
